TNNI3 and Myocardial fibrosis: Monitoring NLR, PLR, NT-proBNP, ST2/IL-33R, and cTn I in these patients receiving 131I treatment may help identify those at risk of developing cardiac complications, including heart failure, myocardial fibrosis, and chronic cardiomyopathy.